It is important to acknowledge that our in vitro model using PHD2-silenced pulmonary ECs cannot fully replicate the complex effects and underlying mechanisms of PHD2 deficiency in a heterogeneous and multifaceted disease like PAH, which affects various cell types in the pulmonary vasculature. This evidence concerns the gene EGLN1 and pulmonary arterial hypertension.